Company Profile
MacroGenics Stock Price, News & Analysis
- Ticker:
- MGNX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.01 USD (+2.82%)
Close
Last updated: August 6, 2026
257M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, MGNX closed up 2.82% at $4.01. No new same-company headline was identified in the current news window.
Company overview
Antibody Engineering Company
MacroGenics develops antibody-based cancer therapies using internal platforms for monoclonal antibodies, bispecific molecules, and antibody-drug conjugates.
ADC Portfolio
MGC026 targets B7-H3 and is in Phase 1 dose expansion, while MGC028 targets ADAM9 and is in Phase 1 dose escalation across advanced solid tumors.
Focused R&D Model
Following divestiture of its manufacturing operation, MacroGenics is concentrating resources on drug discovery, clinical development, partnerships, and royalty interests such as ZYNYZ.
Future catalysts
Initial Phase 1 clinical data for the ADAM9-targeting ADC MGC028 are expected in the second half of 2026.
An IND submission for preclinical ADC MGC030 is planned for the third quarter of 2026.
Recent news
- 01
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
Source: MacroGenics
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of MacroGenics (MGNX)?
MacroGenics (MGNX) most recently closed at 4.01 USD, a +2.82% move versus the previous session.
What is the market cap of MacroGenics (MGNX)?
MacroGenics currently has a market capitalization of 257M USD on BioPharmSignal.
What does MacroGenics do?
Antibody Engineering Company MacroGenics develops antibody-based cancer therapies using internal platforms for monoclonal antibodies, bispecific molecules, and antibody-drug conjugates. ADC Portfolio MGC026 targets B7-H3 and is in Phase 1 dose expansion, while MGC028 targets ADAM9 and is in Phase 1 dose escalation across advanced solid tumors. Focused R&D...
On which exchange is MGNX stock listed?
MacroGenics (MGNX) is associated with NASDAQ, United States, Biopharma.
What is Antibody?
Antibody Engineering Company MacroGenics develops antibody-based cancer therapies using internal platforms for monoclonal antibodies, bispecific molecules, and antibody-drug conjugates.
Which conditions is MacroGenics targeting with Antibody?
MacroGenics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does MacroGenics describe recent progress with Antibody?
Initial Phase 1 clinical data for the ADAM9-targeting ADC MGC028 are expected in the second half of 2026. An IND submission for preclinical ADC MGC030 is planned for the third quarter of 2026.
What is Engineering?
Antibody Engineering Company MacroGenics develops antibody-based cancer therapies using internal platforms for monoclonal antibodies, bispecific molecules, and antibody-drug conjugates.